M F Fassotte

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.

G. Jerusalem, P. Rigo, G. Fillet, 1999, Blood.

Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma.

G. Jerusalem, P. Rigo, G. Fillet, 1999, Nuclear medicine communications.

Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.

R. Hustinx, G. Jerusalem, P. Rigo, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.

G. Jerusalem, P. Rigo, G. Fillet, 2001, Haematologica.